Trial Profile
A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Gontivimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Respire
- Sponsors Ablynx
- 02 Feb 2019 The trial has been completed in United Kingdom, according to the European Clinical Trials Database record.
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2018 This trial was completed in Latvia (End date: 2018-05-25).